Literature DB >> 3015193

Reduced risk of recurrent leukaemia in bone marrow transplant recipients after cytomegalovirus infection.

B Lönnqvist, O Ringdèn, P Ljungman, B Wahren, G Gahrton.   

Abstract

The first 72 consecutive bone-marrow transplant recipients with haematological malignancies (29 with acute nonlymphoblastic leukaemia, 31 with acute lymphoblastic leukaemia, nine with CML and three with myelofibrosis, IgA myeloma and T-cell lymphoma, respectively) were investigated for the frequency of relapses 1 year or later after bone-marrow transplantation. Seven relapses occurred from 30 to 850 d after transplantation (median 180 d). All relapses occurred in patients with acute leukaemia less than or equal to 18 years of age with a high risk for relapse, i.e. transplanted in second or later remission or with more than 10% blasts in the marrow before transplantation. Among all patients the probability of relapse was increased in patients without cytomegalovirus (CMV) infection (P = 0.001) and in patients without chronic GVHD (P = 0.049). Among leukaemic patients less than or equal to 18 years of age with a high risk of relapse all relapses occurred in patients (n = 11) without CMV infection, whereas no relapses were seen in patients (n = 13) with CMV infection (P = 0.006). Known risk factors for leukaemic relapse were comparable in both groups.

Entities:  

Mesh:

Year:  1986        PMID: 3015193     DOI: 10.1111/j.1365-2141.1986.tb07551.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  23 in total

Review 1.  The Past, Present, and Future of NK Cells in Hematopoietic Cell Transplantation and Adoptive Transfer.

Authors:  Frank Cichocki; Michael R Verneris; Sarah Cooley; Veronika Bachanova; Claudio G Brunstein; Bruce R Blazar; John Wagner; Heinrich Schlums; Yenan T Bryceson; Daniel J Weisdorf; Jeffrey S Miller
Journal:  Curr Top Microbiol Immunol       Date:  2016       Impact factor: 4.291

2.  Not just leukemia: CMV may protect against lymphoma recurrence after allogeneic transplant.

Authors:  Jonathan U Peled; Robert R Jenq
Journal:  Leuk Lymphoma       Date:  2016-10-12

3.  Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT.

Authors:  M A Kharfan-Dabaja; M Labopin; A Bazarbachi; R M Hamladji; D Blaise; G Socié; B Lioure; A Bermudez; L Lopez-Corral; R Or; W Arcese; N Fegueux; A Nagler; M Mohty
Journal:  Bone Marrow Transplant       Date:  2014-06-30       Impact factor: 5.483

4.  Lymphocyte expansion after unrelated cord blood allogeneic stem cell transplantation in adults.

Authors:  Y Le Bris; T Guillaume; A Ménard; M Illiaquer; J Martin; S Malard; A Duquesne; P Peterlin; C Debord; N Robillard; M Eveillard; S Wuillème; J Delaunay; M Mohty; A Garnier; P Moreau; M C Béné; P Chevallier
Journal:  Bone Marrow Transplant       Date:  2017-01-30       Impact factor: 5.483

5.  Cytomegalovirus induces strong antileukemic effect in acute myeloid leukemia patients following sibling HSCT without ATG-containing regimen.

Authors:  Xiebing Bao; Qian Zhu; Shengli Xue; Xiaohui Hu; Xiao Ma; Feng Chen; Suning Chen; Aining Sun; Depei Wu; Jianhua Yu; Xiaojin Wu; Huiying Qiu
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

6.  CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia.

Authors:  Margaret L Green; Wendy M Leisenring; Hu Xie; Roland B Walter; Marco Mielcarek; Brenda M Sandmaier; Stanley R Riddell; Michael Boeckh
Journal:  Blood       Date:  2013-06-06       Impact factor: 22.113

7.  Differential requirements for myeloid leukemia IFN-γ conditioning determine graft-versus-leukemia resistance and sensitivity.

Authors:  Catherine Matte-Martone; Jinling Liu; Meng Zhou; Maria Chikina; Douglas R Green; John T Harty; Warren D Shlomchik
Journal:  J Clin Invest       Date:  2017-06-12       Impact factor: 14.808

Review 8.  Correlation of pretransplant viral serology and complications of bone marrow transplantation.

Authors:  O Ringdén
Journal:  Ann Hematol       Date:  1992-06       Impact factor: 3.673

9.  UV-inactivated HSV-1 potently activates NK cell killing of leukemic cells.

Authors:  Ismael Samudio; Katayoun Rezvani; Hila Shaim; Elyse Hofs; Mor Ngom; Luke Bu; Guoyu Liu; Jason T C Lee; Suzan Imren; Vivian Lam; Grace F T Poon; Maryam Ghaedi; Fumio Takei; Keith Humphries; William Jia; Gerald Krystal
Journal:  Blood       Date:  2016-03-03       Impact factor: 22.113

10.  Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis.

Authors:  Pierre Teira; Minoo Battiwalla; Muthalagu Ramanathan; A John Barrett; Kwang Woo Ahn; Min Chen; Jaime S Green; Ayman Saad; Joseph H Antin; Bipin N Savani; Hillard M Lazarus; Matthew Seftel; Wael Saber; David Marks; Mahmoud Aljurf; Maxim Norkin; John R Wingard; Caroline A Lindemans; Michael Boeckh; Marcie L Riches; Jeffery J Auletta
Journal:  Blood       Date:  2016-02-16       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.